Stockholders Approve Doubling Authorized Shares and Expanding Stock Incentive Plan

summarizeSummary

Trevi Therapeutics stockholders approved a major increase in authorized common stock to 400 million shares and added 8 million shares to its stock incentive plan, providing significant flexibility for future capital and compensation needs but also enabling substantial potential dilution.

check_boxKey Events

• Authorized Shares Doubled

  Stockholders approved an amendment to increase the number of authorized common stock from 200,000,000 shares to 400,000,000 shares, effective June 3, 2026. This provides significant headroom for future capital raises or other corporate actions.

• Stock Incentive Plan Expanded

  Stockholders approved the Amended and Restated 2019 Stock Incentive Plan, increasing the number of shares available for issuance under the plan by 8,000,000 shares for equity compensation. This represents a potential dilution of approximately 5.6% of the current market capitalization.

• Director Elected

  Michael Heffernan was elected to the Board as a Class I director for a term expiring at the 2029 annual meeting of stockholders.

• Auditor Ratified

  The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified by stockholders.

auto_awesomeAnalysis

Trevi Therapeutics' stockholders approved a significant increase in the company's authorized common stock, doubling it from 200 million to 400 million shares. This provides substantial headroom for future capital raises, strategic transactions, or other corporate purposes. Additionally, shareholders approved an amendment to the 2019 Stock Incentive Plan, adding 8 million shares for equity compensation, which represents a notable potential for future dilution for existing shareholders. These approvals finalize proposals previously announced in April, giving the company significant flexibility in its capital structure and compensation strategy.